Sigilon Therapeutics, Inc(NASDAQ:SGTX) 
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is als...
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2023-02-13
P
O 0.69
H 0.71
L 0.64
C 0.68
V 38,616
10EMA 0.68
20EMA 0.68
60EMA 0.68
120EMA 0.68
250EMA 0.68